Source-grounded facts extracted from ZEVRA THERAPEUTICS, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Christopher A. Posner was appointed as Director at ZEVRA THERAPEUTICS, INC..
“On November 28, 2022, the board of directors (the “Board”) of KemPharm, Inc. (the “Company”) appointed Christopher A. Posner to serve as a director of the Company, effective immediately.”
ZEVRA THERAPEUTICS, INC. reported the third quarter ended September 30, 2022 results: revenue $2.9 million, net income ($6.6) million, or ($0.19) per basic and diluted share.
“strategy could provide further capital flexibility and extend the operating cash runway. Overview of Third Quarter 2022 Financial Results: Net revenue for Q3 2022 was $2.9 million, as compared to Q3 2021 net revenue of $2.0 million. The period-over-period increase was primarily attributed to revenue from the arimoclomol Early Access Program (EAP) in”
Richard W. Pascoe was appointed as Executive Chairman at ZEVRA THERAPEUTICS, INC..
“On November 5, 2021, the Board of Directors of KemPharm appointed Richard W. Pascoe as KemPharm’s Executive Chairman.”
Tamara A. Seymour was appointed as Director and Chair of the Audit Committee at ZEVRA THERAPEUTICS, INC..
“the board of directors (the “Board”) of KemPharm, Inc. (the “Company”) appointed Tamara A. Seymour to serve as a director of the Company and as the chair of the Company’s audit committee.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.